loadpatents
name:-0.020336866378784
name:-0.020703077316284
name:-0.0018880367279053
MCKEARN; John P. Patent Filings

MCKEARN; John P.

Patent Applications and Registrations

Patent applications and USPTO patent grants for MCKEARN; John P..The latest application filed is for "novel monoclonal antibodies to osteopontin".

Company Profile
1.19.14
  • MCKEARN; John P. - St. Louis MO
  • McKearn; John P. - San Diego CA
  • McKearn; John P. - Glencoe MO
  • McKearn; John P - St. Louis MO
  • McKearn, John P. - Wildwood MO
  • McKearn, John P. - Pacific MO
  • McKearn; John P - Pacific MO
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Novel Monoclonal Antibodies To Osteopontin
App 20190367602 - MCKEARN; John P. ;   et al.
2019-12-05
Methods For The Modulation Of Crp By The Selective Modulation Of Ppar Delta
App 20080004281 - Rao; Tadimeti S. ;   et al.
2008-01-03
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
Grant 6,916,800 - McKearn , et al. July 12, 2
2005-07-12
Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
App 20050059149 - Bauer, S. Christopher ;   et al.
2005-03-17
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
App 20050058725 - McKearn, John P. ;   et al.
2005-03-17
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
Grant 6,858,598 - McKearn , et al. February 22, 2
2005-02-22
Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
App 20050037090 - McKearn, John P. ;   et al.
2005-02-17
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
Grant 6,833,373 - McKearn , et al. December 21, 2
2004-12-21
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
App 20040234624 - McKearn, John P. ;   et al.
2004-11-25
Multi-functional hematopoietic fusion proteins between sequence rearranged G-CSF receptor agonists and other hematopoietic factors
App 20040171115 - Feng, Yiqing ;   et al.
2004-09-02
Circular permuteins of flt3 ligand
App 20040127410 - McWherter, Charles A. ;   et al.
2004-07-01
Fused G-CSF and IL-3 proteins and uses thereof
Grant 6,730,303 - Feng , et al. May 4, 2
2004-05-04
Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
Grant 6,689,787 - McKearn , et al. February 10, 2
2004-02-10
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
Grant 6,649,645 - McKearn , et al. November 18, 2
2003-11-18
Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
App 20030194783 - McKearn, John P. ;   et al.
2003-10-16
Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
App 20030185790 - Bauer, S. Christopher ;   et al.
2003-10-02
Methods of ex-vivo expansion of hematopoeitic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
App 20030165461 - Bauer, S. Christopher ;   et al.
2003-09-04
Method of ex-vivo expansion of hematopoeitic cells using interleukin-3 (IL-3) multiple mutation polypeptides
App 20030103936 - Bauer, S. Christopher ;   et al.
2003-06-05
Antiangiogenic combination therapy for the treatment of cancer
App 20020103141 - McKearn, John P. ;   et al.
2002-08-01
Methods of using multivariant IL-3 hematopoiesis fusion protein
Grant 6,361,977 - Bauer , et al. March 26, 2
2002-03-26
Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
App 20010016602 - Liang, Chi-Dean ;   et al.
2001-08-23
Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
Grant 6,265,439 - Mueller , et al. July 24, 2
2001-07-24
G-CSF receptor agonists
Grant 6,100,070 - Zurfluh , et al. August 8, 2
2000-08-08
Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
Grant 6,093,395 - Bauer , et al. July 25, 2
2000-07-25
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
Grant 6,066,318 - Feng , et al. May 23, 2
2000-05-23
Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
Grant 6,030,812 - Bauer , et al. February 29, 2
2000-02-29
Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
Grant 6,022,535 - Bauer , et al. February 8, 2
2000-02-08
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
Grant 5,738,849 - Bauer , et al. * April 14, 1
1998-04-14
Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
Grant 5,501,962 - Braford-Goldberg , et al. March 26, 1
1996-03-26
Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
Grant 5,486,539 - Liang , et al. January 23, 1
1996-01-23
Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
Grant 5,451,604 - Mueller , et al. September 19, 1
1995-09-19
Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
Grant 5,247,119 - Fowler , et al. September 21, 1
1993-09-21
Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
Grant 5,162,569 - Liang , et al. November 10, 1
1992-11-10
Company Registrations
SEC0001240120MCKEARN JOHN P

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed